» Articles » PMID: 21121985

Increased Connective Tissue Growth Factor Associated with Cardiac Fibrosis in the Mdx Mouse Model of Dystrophic Cardiomyopathy

Overview
Publisher Wiley
Specialty Pathology
Date 2010 Dec 3
PMID 21121985
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiomyopathy contributes to morbidity and mortality in Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disorder. A major feature of the hearts of DMD patients and the mdx mouse model of the disease is cardiac fibrosis. Connective tissue growth factor (CTGF) is involved in the fibrotic process in many organs. This study utilized the mdx mouse model to assess the role of CTGF and other extracellular matrix components during the development of fibrosis in the dystrophic heart. Left ventricular function of mdx and control mice at 6, 29 and 43 weeks was measured by echocardiography. Young (6 weeks old) mdx hearts had normal function and histology. At 29 weeks of age, mdx mice developed cardiac fibrosis and increased collagen expression. The onset of fibrosis was associated with increased CTGF transcript and protein expression. Increased intensity of CTGF immunostaining was localized to fibrotic areas in mdx hearts. The upregulation of CTGF was also concurrent with increased expression of tissue inhibitor of matrix metalloproteinases (TIMP-1). These changes persisted in 43 week old mdx hearts and were combined with impaired cardiac function and increased gene expression of transforming growth factor (TGF)-β1 and matrix metalloproteinases (MMP-2, MMP-9). In summary, an association was observed between cardiac fibrosis and increased CTGF expression in the mdx mouse heart. CTGF may be a key mediator of early and persistent fibrosis in dystrophic cardiomyopathy.

Citing Articles

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model.

Hasegawa J, Nagata T, Ihara K, Tanihata J, Ebihara S, Yoshida-Tanaka K Nat Commun. 2024; 15(1):7530.

PMID: 39327422 PMC: 11427662. DOI: 10.1038/s41467-024-48204-5.


Functional cardiac consequences of β-adrenergic stress-induced injury in a model of Duchenne muscular dystrophy.

Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S Dis Model Mech. 2024; 17(10).

PMID: 39268580 PMC: 11488649. DOI: 10.1242/dmm.050852.


Functional cardiac consequences of β-adrenergic stress-induced injury in the mouse model of Duchenne muscular dystrophy.

Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S bioRxiv. 2024; .

PMID: 38659739 PMC: 11042272. DOI: 10.1101/2024.04.15.589650.


Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy.

Connolly A, Zaidman C, Brandsema J, Phan H, Tian C, Zhang X J Neuromuscul Dis. 2023; 10(4):685-699.

PMID: 37248912 PMC: 10357134. DOI: 10.3233/JND-230019.


Inflammasome Activity in the Skeletal Muscle and Heart of Rodent Models for Duchenne Muscular Dystrophy.

Onodi Z, Szabo P, Kucsera D, Pokreisz P, Dostal C, Hilber K Int J Mol Sci. 2023; 24(10).

PMID: 37239853 PMC: 10218525. DOI: 10.3390/ijms24108497.


References
1.
Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K . Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006; 47(4):711-7. DOI: 10.1161/01.HYP.0000208840.30778.00. View

2.
Candido R, Forbes J, Thomas M, Thallas V, Dean R, Burns W . A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003; 92(7):785-92. DOI: 10.1161/01.RES.0000065620.39919.20. View

3.
Deschamps A, Spinale F . Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006; 69(3):666-76. DOI: 10.1016/j.cardiores.2005.10.004. View

4.
Bushby K, Muntoni F, Bourke J . 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003; 13(2):166-72. DOI: 10.1016/s0960-8966(02)00213-4. View

5.
Wang X, McLennan S, Allen T, Twigg S . Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes. J Cell Commun Signal. 2010; 4(1):15-23. PMC: 2821474. DOI: 10.1007/s12079-009-0083-1. View